ScholarIQanswers from OpenAlex & ORCID
Junji Tsurutani
ResearcherPublications, citations & collaboration network
Junji Tsurutani is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Junji Tsurutani have?
ScholarIQindexed works
Junji Tsurutani has 379 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Junji Tsurutani have?
ScholarIQcitation count
Junji Tsurutani has 19,284 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Junji Tsurutani?
ScholarIQh-index
Junji Tsurutani has an h-index of 53 in OpenAlex.
What is the i10-index of Junji Tsurutani?
ScholarIQi10-index
Junji Tsurutani has an i10-index of 152 in OpenAlex.
What is the ORCID of Junji Tsurutani?
ScholarIQorcid
The ORCID for Junji Tsurutani is on the source record.
What is the OpenAlex record for Junji Tsurutani?
ScholarIQopenalex
The OpenAlex for Junji Tsurutani is on the source record.
What are the most-cited papers on Junji Tsurutani?
ScholarIQmost cited works
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
Shanu Modi, William Jacot, Toshinari Yamashita, Joohyuk Sohn, María Vidal, Eriko Tokunaga, Junji Tsurutani, Naoto T. Ueno, Aleix Prat, Yee Soo Chae, Keun Seok Lee, Naoki Niikura, Yeon Hee Park, Binghe Xu, Xiaojia Wang, Miguel Gil‐Gil, Wěi Li, Jean‐Yves Pierga, Seock‐Ah Im, Halle C. F. Moore, Hope S. Rugo, Rinat Yerushalmi, Flora Zagouri, Andrea Gombos, Sung‐Bae Kim, Qiang Liu, Ting Luo, Cristina Saura, Peter Schmid, Tao Sun, Dhiraj Gambhire, Lotus Yung, Yibin Wang, Jasmeet Singh, Patrik Vitazka, Gerold Meinhardt, Nadia Harbeck, David Cameron
HER2-Mediated Internalization of Cytotoxic Agents in <i>ERBB2</i> Amplified or Mutant Lung Cancers
Bob T. Li, Flavia Michelini, Sandra Misale, Emiliano Cocco, Laura Baldino, Yanyan Cai, Sophie Shifman, Hai‐Yan Tu, Mackenzie L. Myers, Chong‐Rui Xu, Marissa S. Mattar, Inna Khodos, Megan Little, Besnik Qeriqi, Gregory Weitsman, Clare J. Wilhem, Alshad S. Lalani, Irmina Diala, Rachel A. Freedman, Nancy U. Lin, David B. Solit, Michael F. Berger, Paul R. Barber, Tony Ng, Michael Offin, James M. Isbell, David R. Jones, Helena A. Yu, Sheeno Thyparambil, Wei‐Li Liao, Anuja Bhalkikar, Fabiola Cecchi, David M. Hyman, Jason S. Lewis, Darren J. Buonocore, Alan L. Ho, Vicky Makker, Jorge S. Reis‐Filho, Pedram Razavi, Maria E. Arcila, Mark G. Kris, John T. Poirier, Ronglai Shen, Junji Tsurutani, Gary A. Ulaner, Elisa de Stanchina, Neal Rosen, Charles M. Rudin, Maurizio Scaltriti
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study
Aditya Bardia, Ian E. Krop, Takahiro Kogawa, Dejan Juric, Anthony W. Tolcher, Erika Hamilton, Toru Mukohara, Aaron Lisberg, Toshio Shimizu, Alexander I. Spira, Junji Tsurutani, Senthil Damodaran, Kyriakos P. Papadopoulos, Jonathan Greenberg, Fumiaki Kobayashi, Hong Zebger‐Gong, Rie Wong, Yui Kawasaki, Tadakatsu Nakamura, Funda Meric‐Bernstam